Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for CTLA- 4
Most Correlated Studies
- Regulatory T (Treg) cells and conventional T cells reponses to different factors and conditions
- Metastatic melanoma tumors of patients treated with anti-CTLA-4 therapy or anti-PD-1 therapy
- Kidney, lung, tumor, liver, muscle & heart of mice with MC38 tumor treated with anti-PD-1 & CTLA-4
- CD8+ T cells specific for Ova peptide SIINFEKL treated with rapamycin and anti-CTLA4 post activation
- CD4+ T cells of RAG2-null 5C.C7 mice with or without CTLA4 after adoptive transfer and immunization
Most Relevant Literature
- Mechanistic Insights into the Inhibition of a Common CTLA-4 Gene Mutation in the Cytoplasmic Domain.
- CTLA-4 expression and polymorphisms in Schizophrenia; a systematic review of literature.
- Targeting cytotoxic lymphocyte antigen 4 (CTLA-4) in breast cancer.
- The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?
- DECTIN-1: A modifier protein in CTLA-4 haploinsufficiency.
Most Relevant Clinical Trials
- PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcin…
- XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint In…
- Clinical Study of Recombinant Humanized CTLA-4-FC Fusion Protein Injection in Healthy Subjects
- PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer
- Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
